In a recent study Kamber et al. 1 evaluated the prognostic significance of herpes zoster (HZ) in 191 consecutive myeloma patients treated with high-dose melphalan chemotherapy followed by autologous stem cell transplantation (ASCT). The study provides interesting and important data on the burden of HZ in this patient population. However, immortal person-time bias likely affected the methods used to estimate the effect of HZ on survival after ASCT, leading to the spurious appearance of a protective effect.
Kamber et al. 1 reported a 66% reduction in mortality among patients with HZ after ACST compared with patients without HZ after ASCT, which suggests that HZ infection after ASCT is more beneficial than most tumor-directed therapies. In the discussion, the authors expressed their surprise about the results, but nevertheless put forth some potential biological explanations. Because HZ can take a complicated course in patients with haematological malignancies 2 and may correlate with degree of immunosuppression, 3, 4 their results seem biologically implausible. More likely, the decreased mortality in patients with HZ results from immortal person-time bias.
Immortal person-time bias (also known as guarantee-time bias, survivor treatment selection bias, or survivor bias) arises when the outcome of study participants is compared across groups that are defined by an event occurring during follow-up. [5] [6] [7] Use of such definitions requires that those who satisfy the definition survive until the defining event occurs. From the perspective of the data analysis, persons who experience the event appear to be 'immortal' for the time between study entry (that is, follow-up start) and the defining event. When this 'immortal' person-time is included in the denominator of the mortality rate, the result is a substantial bias in favor of the group that experienced the event. The bias is particularly important in studies of mortality in patients with poor short-term survival, because persons with short survival are overrepresented in the group that did not experience the event.
Kamber et al. 1 analyzed the association between HZ and survival following ASCT by computing follow-up time from the time of ASCT to death. We have illustrated the design in Figure 1 . In patients who had HZ, the exposure-defining HZ infection occurred after the start of follow-up. Had these patients died before their HZ infection, they would have been counted among those who had died without HZ infection. From the perspective of the study's data analysis, patients were 'immortal' from the ASCT to the HZ infection, and this 'immortal' person-time was added to the denominator of the mortality rate for the HZ infected group. The inclusion of immortal person-time therefore resulted in the appearance of an artificial survival advantage for HZ patients. 7 Indeed, Figure 2a in the paper by Kamber et al.
1 supports this statement. In the figure, the line representing patients with HZ after ASCT does not decline at all until~24 months after ASCT. One hundred percent survival during the first two years of followup is highly unlikely in a cohort of myeloma patients treated with ASCT, but is readily explained by the immortal person-time bias.
Unfortunately, immortal person-time bias is not unheard of in cancer research, with many other examples published to date. Anytime an exposure-defining event occurs during follow-up time and the follow-up time preceding the event is included in the mortality rate for those with the event, immortal person-time bias must be suspected. For example, many trials of chemotherapy in cancer patients have been published comparing the survival of responders and nonresponders without taking into account that patients with high mortality will not have a chance to become responders, thereby resulting in an overestimate of the treatment effect. 5 Similarly, some studies examining tamoxifen effectiveness in the treatment of breast cancer by CYP2D6 genotype have been biased by inclusion of the time between breast cancer diagnosis and drawing of blood sample used to assess genotype in the analysis. 8 Another study that received much attention for inclusion of immortal person-time reported that diagnosis of non-melanoma skin cancer, used as a proxy for sun exposure, was associated with halving of all-cause mortality following age 40 years compared with individuals who did not receive this cancer diagnosis. 6, 9 Because individuals with non-melanoma skin cancer had to survive long enough to be diagnosed with this cancer, which typically occurs at high age, their survival advantage was inherent in the study design. 6 In fact, a subanalysis in the paper using a case-control design showed that the association virtually disappeared, thus confirming the presence of substantial immortal person-time bias in the main analysis. 6, 9 There are also many notorious examples of immortal persontime bias outside cancer research, including studies showing that persons who reach higher ranks have increased longevity. 10 For example, a study published in Annals of Internal Medicine showed that Academy Award winners live longer than nonwinners, but this is only because the winners must live long enough to receive an award.
As illustrated by the aforementioned examples, immortal person-time bias can be overlooked if person-time before the exposure-defining event is counted in the numerator of the exposed rate. [5] [6] [7] [8] The simple solution to circumvent the bias is to include only time elapsed from the last exposure-defining condition in the calculation of person-time for the exposed cohort. In practice, there are several methods available, including conditional landmark analysis, the extended Cox model with timevarying covariates, and the inverse probability-weighted model. 5 These different approaches for dealing with immortal person-time bias have been described in detail elsewhere. 5 In summary, immortal person-time bias in the study by Kamber et al. precludes any inference that HZ after ASCT improves survival in myeloma patients. Reanalysis with appropriate allocation of the person-time in study cohorts may remove or even reverse the direction of the association, thereby confirming what may have been the a priori hypothesis of the authors.
